Jasper Therapeutics, Inc.

Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.

JSPR | US

Overview

Corporate Details

ISIN(s):: US4718712023 (+3 more)
LEI:
Country:: United States of America
Address:: 2200 BRIDGE PKWY SUITE #102, 94065 REDWOOD CITY
Website:: https://jaspertx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for mast cell-driven diseases and as a conditioning agent for hematopoietic stem cell transplantation. The company's lead product candidate is briquilimab, a targeted anti-KIT (CD117) monoclonal antibody designed to deplete mast cells. Jasper is evaluating briquilimab in clinical studies for the treatment of chronic immunological and inflammatory diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to develop safer and more effective therapies for patients with serious chronic diseases by harnessing the power of mast cell depletion.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Jasper Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Jasper Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Jasper Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
IOVANCE BIOTHERAPEUTICS, INC. Developing personalized T-cell immunotherapies (TIL) to fight solid tumors and blood cancers.	United States of America	IOVA
Ipsen Developing innovative medicines for Oncology, Rare Diseases, and Neuroscience.	France	IPN
IRLAB Therapeutics Developing novel drugs for Parkinson's disease and other neurodegenerative CNS disorders.	Sweden	IRLAB
IRONWOOD PHARMACEUTICALS INC Develops and commercializes therapies for GI diseases like IBS-C and chronic constipation.	United States of America	IRWD
ISU Abxis Co., Ltd. Developing antibody-based immunotherapies for oncology and rare diseases.	South Korea	086890
Iterum Therapeutics plc Develops novel oral & IV anti-infectives to combat multi-drug resistant pathogens.	United States of America	ITRM
IVF HARTMANN Holding AG Produces and distributes medical supplies, wound care, and hygiene items for global healthcare.	Switzerland	VBSN
Jade Biosciences, Inc. Clinical-stage biotech developing therapies for autoimmune and inflammatory diseases.	United States of America	JBIO
Jaguar Health, Inc. Develops plant-based, non-opioid GI therapies for humans and animals.	United States of America	JAGX
Janux Therapeutics, Inc. Developing tumor-activated immunotherapies to treat cancer while minimizing systemic toxicities.	United States of America	JANX